New drug ICT01 aims to rally Body's defenses against tough cancers
NCT ID NCT04243499
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tests a new drug called ICT01, given alone or with the immunotherapy Keytruda, in people with advanced solid tumors or blood cancers that have come back or not responded to treatment. The goal is to see if ICT01 is safe and can help control the cancer by activating a specific type of immune cell. About 292 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
CHU Lyon
Lyon, France
-
CHU Nantes
Nantes, 44093, France
-
CHU Poitiers
Poitiers, 86000, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Hospitalier Lyon Sud
Lyon, 69310, France
-
Centre Lyon Berard
Lyon, France
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Gustave Roussy
Paris, France
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Haut Leveque
Bordeaux, 33600, France
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Institut Bergonie
Bordeaux, 33000, France
-
Institut Curie
Paris, 75248, France
-
Institut Jules Bordet
Brussels, Belgium
-
Institut Paoli-Calmettes
Marseille, France
-
Institute of Cancer Research
London, United Kingdom
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
-
Pitie-Salpetriere
Paris, 75013, France
-
START Barcelone HM Nou Delfos
Barcelona, 08023, Spain
-
START Madrid-FJD, Hospital Fundación Jiménez Díaz
Madrid, 28040, Spain
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
US Oncology Research
Irving, Texas, 75063, United States
-
University Carl Gustav Carus Clinical Trial Unit
Dresden, Germany
-
University of Washington
Seattle, Washington, 98133, United States
-
Vall d'Hebron Instiute of Oncology
Barcelona, Spain
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
-
universitatklinikum Wurburg
Würzburg, Germany
Conditions
Explore the condition pages connected to this study.